2018 American Transplant Congress
The Impact of Rituximab Dose on Hepatitis B Virus Reactivation in HBsAg-Negative/anti-HBc-Positive Kidney Transplant Recipients
Background: Hepatitis B virus (HBV) reactivation is well-recognized complication of rituximab. Although use of rituximab for sensitized patients continues to increase in kidney transplantation, the…2018 American Transplant Congress
Impacts of HBsAg Seropositive Status on Patient and Graft Survival after Kidney Transplantation in the Era of New Antiviral Therapy: A Meta-Analysis
BACKGROUND: An association between HBsAg seropositive status and increased mortality after kidney transplantation has been demonstrated in previous studies over the past decade. Although chronic…2017 American Transplant Congress
A Low-Dose Anti-Hepatitis B Immunoglobulin Regimen for Prophylaxis of Hepatitis B Recurrence.
Liver and Transplantation Surgery, Chang-Gung Memorial Hospital, Taoyuan, Taiwan
Background: Hepatitis B virus (HBV)-related liver disease is the major indication of liver transplantation in Asian countries. Combination of anti-hepatitis B immunoglobulin (HBIg) and anti-viral…2017 American Transplant Congress
Hepatitis B Virus Infection Is Associated with Recurrent Nephropathy After Kidney Transplantation.
Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Background Hepatitis B virus(HBV) infection can cause HBV associated nephropathy, and is one of the major reasons for secondary nephropathy. We carried out a retrospective…2017 American Transplant Congress
Favorable Long-Term Prognosis of Hepatitis B Surface Antigen Positive Intrahepatic Cholangiocarcinoma for Both Hepatic Resection and Incidental Liver Transplantation via Inhibiting Cancer-Associated Lymphangiogenesis.
Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Background: In recent years, a few publications indicated that hepatitis B virus (HBV) infection is associated with the prognosis of patients with ICC after resection.…2017 American Transplant Congress
Blockade of Tim-3 and PD-1 Reverses Dysfunctions of Tumor Infiltrating Lymphocytes in HBV Related Hepatocellular Carcinoma.
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
The immunosuppression of tumor infiltrating lymphocytes (TILs) is associated with rapid progress of hepatitis B virus related hepatocellular carcinoma (HBV-HCC). The inhibition molecules of T…2017 American Transplant Congress
The Evolution of Hepatitis B Surface Antibody (Anti-HBs) Titer of the Kidney Transplant Recipients: A 5-Year Experience Guideline for the Optimal Maintaining Immunization.
Division of Nephrology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand
Background: Immunization against hepatitis B virus (HBV) in kidney transplantation (KT) recipients is recommended as KDIGO guideline. Although hepatitis B surface antibody (anti-HBs) titer of…2016 American Transplant Congress
Implementation of a Risk Stratified Approach for Prevention of Hepatitis B Reactivation Post Kidney Transplant.
A large percentage of patients with end stage renal disease are known to be Hepatitis B virus (HBV) positive. A 2015 consensus guideline on use…2016 American Transplant Congress
Hepatitis B Reactivation Among Non-Liver Solid Organ Transplant Recipients.
IntroductionThe purpose of this study was to evaluate the incidence of post-transplant hepatitis B (HBV) reactivation in patients who have previously cleared hepatitis B surface…2016 American Transplant Congress
Prophylactic Anti-Virus Therapy, Is It Necessary to Occult Hepatitis B Virus Carriers with HBsAg(-) and HBcAb(+) After Kidney Transplantation?
Background Hepatitis B virus(HBV) infection is common among uremia patients in China. Many patients received kidney transplantation are occult HBV carriers with HBsAg(-) and HBcAb(+)…
American Transplant Congress abstracts